Untargeted Metabolomics

Service Description

The metabolome refers to the collection of all small molecule metabolites (< 1500 Da) in cells, tissues, organs or biological organisms, metabolites produced by microorganisms, and all exogenous substances from heterologous organisms.
Metabolomics is a research method comprising qualitative and quantitative analysis of all metabolites in an organism. It involves the comparison of the metabolome between control and test groups (for example, a specific gene mutation or environmental change), screening of differential metabolites by statistical analysis, and metabolic pathway analysis of differential metabolites, to identify differences between metabolites and physiological/pathological changes.
Untargeted Metabolomics is an important branch of metabolomics and designed to obtain a metabolite profile and screen for differentially-expressed molecules in the sample. In turn, untargeted medical metabolomics is an important branch of untargeted metabolomics. As many metabolites from different cell samples, microbial samples, animal samples or clinical samples as possible are measured and compared between control and test groups without bias.
BGI has extensive experience in the field of untargeted medical metabolomics with well-developed reliable workflows using market leading technologies and a bioinformatics infrastructure that is second to none.

Mass Spectrometry Service Specification

Untargeted Metabolomics services are performed using Waters ACQUITY UPLC and cutting-edge mass spectrometer (Q Exactive HF/HF-X and Q-TOF 5600).

Sample Preparation and Services

Increase metabolome depth of coverage using both ACQUITY UPLC BEH C18 and Amide column

(+) and (-) ESI detection by a Q Exactive HF/HF-X mass spectrometer

Quality Standard

Summary includes all methods and data analysis

Reports provided in Excel or PDF format, RAW files available upon request

Turn Around Time

Typical 5-7 weeks after sample receipt for raw data delivery

Research Applications

• Disease biomarkers research
• Pathogenesis and prognosis study on diseases
• Drug compound identification, toxicity assessment and drug efficacy evaluation
• Regulation mechanism of tissue development
• Microbial infection and its pathogenesis
• Animal special behavior mechanism and food/medicinal value research

Service Advantages

State-of-the-art LC-MS/MS systems	Rich large sample experience	High-precision identification results	Strict quality control system
Thermo Q Exactive™ HF-X	High throughput automated sample preparation	Self-built standard library + Thermo mzcloud (4000+)	Strict protocols governing the whole workflow
Resolution up to 24,000, ensuring high spectral quality and accurate results	Real-time monitoring instrument detection process	100% identification is achieved through the standards	Double quality control prcoess of isotopic internal standard and QC samples
		Identification credibility rating

Need a quotation?

Specifications

Increase metabolome depth of coverage using both ACQUITY UPLC BEH C18 and Amide column
(+) and (-) ESI detection by a Q Exactive HF/HF-X mass spectrometer
Summary includes all methods and data analysis
Reports provided in Excel or PDF format, RAW files available upon request
Typical 5-7 weeks after sample receipt for raw data delivery

Sample Requirements

SAMPLE TYPE	RECOMMENDED SAMPLE AMOUNT	MINIMUM SAMPLE AMOUNT
Serum, plasma	≥ 300 µL	≥ 100 µL
Urine	≥ 300 µL	≥ 100 µL
Animal and clinical tissues	≥ 200 mg	≥ 25 mg
Feces and intestinal contents	≥ 200 mg	≥ 25 mg
Cell	1×10^7	5×10^6
Microorganism	≥ 200 mg	≥ 25 mg
Culture medium, fermentation medium	≥ 1 mL	≥ 100 µL
Milk	≥ 1 mL	≥ 100 µL
Other body fluids (amniotic fluid, saliva, hemolymph, cerebrospinal fluid, etc.)	≥ 300 µL	≥ 100 µL

Data Analysis

Data analysis performed with metaX1 and BGI Genomics library
T-test, PCA, PLS-DA, OPLS-DA for differential metabolite identification
Cluster analysis
Metabolite pathway annotation
ROC analysis
Metabolite correlation analysi

Untargeted Metabolomics

Unique DNBSEQ™ Sequencing Technology

BGI’s RNA Sequencing services are typically executed with proprietary DNBSEQ™ sequencing technology platforms, for great sequencing data at some of the lowest costs in the industry. DNBSEQ™ offers advantages in terms of lower amplification error rates and much lower duplication rates. In addition, studies have shown the lower index hopping rate in DNBSEQ™ platforms.